Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01202175
Other study ID # 100353
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date July 2010
Est. completion date June 2013

Study information

Verified date July 2019
Source University of California, San Diego
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators aim to evaluate subjects at high risk of future development of hypertension, those with a family history of hypertension and/or that already have high normal(SBP 120-139 mmHg or DBP 80-89 mmHg) blood pressure. The investigators plan to investigate whether these subjects have the same markers (such as microscopic protein in the urine or C-reactive protein in the blood) in the blood and urine that people with high blood pressure have, and whether they are improved before and after taking the beta-blocker nebivolol.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date June 2013
Est. primary completion date June 2012
Accepts healthy volunteers No
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

- • Prehypertensive male and female subjects with SBP =120-139 or DBP =80-89 with at least one known family member (must be diagnosed prior to the age of 60) with essential hypertension (confirmation may be sought).

- All ethnicities

- Non-smokers and non-drug abusers, no current smoking or illicit drug use in the prior 3 months.

- Aged 18-40 years

- No known serious medical conditions requiring close monitoring from physicians- such as liver impairment, chronic kidney disease, or diabetes mellitus

- Subjects will need to remain in the San Diego area for the duration of the study (10 weeks) and be accessible by telephone or email.

- Female subjects must be willing to use a birth control method, such as abstinence, birth control pills, diaphragm, condom, or intrauterine device to prevent pregnancy during the study.

Exclusion Criteria:

- Subjects with SBP >140 or SBP<120 or DBP >90 and DBP<80

- We will exclude subjects whose family members have known secondary etiologies for hypertension such as hyperaldosteronism or Cushing's Disease.

- Subjects cannot have a chronic medical condition that is actively treated by a physician, such as liver impairment, diabetes, or kidney disease

- History of bronchial asthma or chronic obstructive pulmonary disease

- Subjects cannot be on any anti-hypertensive medications for any reason.

- Subjects may not have previous intolerance, hypersensitivity, or allergy to any beta blocker therapy or may have contraindications to beta blocker therapy such as asthma, bradycardia, etc.

- Subjects may not be taking medications which may affect the metabolism of nebivolol, such as those that inhibit CYP2D6 (such as fluoxetine or cimetidine)

- Nursing women, pregnant women, or those that plan to become pregnant in the study period will also be excluded. (Pregnancy tests will be performed on all female subjects at the start of the study)

- Subjects with pulse rate consistently <60 beats per minute or evidence of arrythmias including atrioventricular block.

- Those that have smoked or used illicit drugs within the past 3 months

- Female subjects that are not willing to use a birth control method, such as abstinence, birth control pills, diaphragm, condom, or intrauterine device to prevent pregnancy during the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Nebivolol
Oral nebivolol 2.5-5mg once daily

Locations

Country Name City State
United States University of California, San Diego La Jolla California

Sponsors (2)

Lead Sponsor Collaborator
University of California, San Diego Forest Laboratories

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Aortic Systolic Blood Pressure (SBP) Basline (visit 1) and 8 weeks (visit 2)
Primary Aortic Diastolic Blood Pressure (DBP) Basline (visit 1) and 8 weeks (visit 2)
Primary Aortic Mean Arterial Pressure (MAP) Basline (visit 1) and 8 weeks (visit 2)
Primary Aortic Pulse Pressure Basline (visit 1) and 8 weeks (visit 2)
Primary Aortic Augmentation Pressure Basline (visit 1) and 8 weeks (visit 2)
Primary Aortic Augmentation Index for Heart Rate Basline (visit 1) and 8 weeks (visit 2)
Primary Pulse Wave Velocity Basline (visit 1) and 8 weeks (visit 2)
Primary Heart Rate, Beats Per a Minute Basline (visit 1) and 8 weeks (visit 2)
Secondary Urinary Nitric Oxide Excretion Basline (visit 1) and 8 weeks (visit 2)
Secondary Urinary Isoprostane Excretion Basline (visit 1) and 8 weeks (visit 2)
Secondary Urinary Hydrogen Peroxide Excretion Baseline (visit 1) and 8 Weeks (visit 2)
Secondary Plasma Interleukin Levels Basline (visit 1) and 8 weeks (visit 2)
See also
  Status Clinical Trial Phase
Terminated NCT04591808 - Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia Phase 3
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT05433233 - Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension N/A
Completed NCT05491642 - A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses Phase 1
Completed NCT03093532 - A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT05529147 - The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
Recruiting NCT06363097 - Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
Recruiting NCT05976230 - Special Drug Use Surveillance of Entresto Tablets (Hypertension)
Completed NCT06008015 - A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers Phase 1
Completed NCT05387174 - Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period N/A
Completed NCT04082585 - Total Health Improvement Program Research Project
Recruiting NCT05121337 - Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension N/A
Withdrawn NCT04922424 - Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men Phase 1
Active, not recruiting NCT05062161 - Sleep Duration and Blood Pressure During Sleep N/A
Not yet recruiting NCT05038774 - Educational Intervention for Hypertension Management N/A
Completed NCT05087290 - LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
Completed NCT05621694 - Exploring Oxytocin Response to Meditative Movement N/A
Completed NCT05688917 - Green Coffee Effect on Metabolic Syndrome N/A
Recruiting NCT05575453 - OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure N/A